4.5 Article

Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity

期刊

AMERICAN HEART JOURNAL
卷 242, 期 -, 页码 61-70

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2021.08.001

关键词

COVID-19; cardiac magnetic resonance imaging; CMR; biomarkers; troponin; NT-proBNP

资金

  1. South-Eastern Norway Regional Health Authority [2017051]

向作者/读者索取更多资源

In patients recovered from moderate-to-severe COVID-19, 21% had abnormal cardiovascular resonance imaging (CMR) 6 months after recovery, which did not correlate with disease severity. Higher cardiovascular biomarkers during COVID-19 were associated with more CMR pathology in recovery, but not significantly after adjusting for confounding factors.
Background Coronavirus disease 2019 (COVID-19) may cause myocardial injury and myocarditis, and reports of persistent cardiac pathology after COVID-19 have raised concerns of long-term cardiac consequences. We aimed to assess the presence of abnormal cardiovascular resonance imaging (CMR) findings in patients recovered from moderate-to-severe COVID-19, and its association with markers of disease severity in the acute phase. Methods Fifty-eight (49%) survivors from the prospective COVID MECH study, underwent CMR median 175 [IQR 105217] days after COVID-19 hospitalization. Abnormal CMR was defined as left ventricular ejection fraction (LVEF) < 50% or myocardial scar by late gadolinium enhancement. CMR indices were compared to healthy controls (n = 32), and to circulating biomarkers measured during the index hospitalization. Results Abnormal CMR was present in 12 (21%) patients, of whom 3 were classified with major pathology (scar and LVEF < 50% or LVEF < 40%). There was no difference in the need of mechanical ventilation, length of hospital stay, and vital signs between patients with vs without abnormal CMR after 6 months. Severe acute respiratory syndrome coronavirus 2 viremia and concentrations of inflammatory biomarkers during the index hospitalization were not associated with persistent CMR pathology. Cardiac troponin T and N-terminal pro-B-type natriuretic peptide concentrations on admission, were higher in patients with CMR pathology, but these associations were not significant after adjusting for demographics and established cardiovascular disease. Conclusions CMR pathology 6 months after moderate-to-severe COVID-19 was present in 21% of patients and did not correlate with severity of the disease. Cardiovascular biomarkers during COVID-19 were higher in patients with CMR pathology, but with no significant association after adjusting for confounders. Trial Registration COVID MECH Study ClinicalTrials.gov Identifier: NCT04314232 (Am Heart J 2021;242:61- 70.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据